Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 22;12(6):e062907. doi: 10.1136/bmjopen-2022-062907

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Study workflow. After patients are diagnosed with malignant peritoneal mesothelioma (MPM), they will undergo a diagnostic laparoscopy (DLS) as a part of standard care. If the disease is deemed resectable, patients will undergo cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) as part of standard care. If the disease is considered not resectable during DLS, patients are eligible for inclusion in the currents study. A port-a-cath (PAC) system will be placed subcutaneously while the catheter tip is placed inside the peritoneal cavity. After surgery, patients will receive weekly cycles of intraperitoneal chemotherapy. CRS-HIPEC, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.